TLP
AXSM icon

Tri Locum Partners’s Axsome Therapeutics AXSM Stock Holding History

Tri Locum Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.7M Buy
219,308
+157,192
+253% +$34.1M 6.6% 6
2026
Q1 		$10.5M Sell
62,116
-139,511
-69% -$24.1M 1.47% 16
2025
Q4 		$36.8M Sell
201,627
-90,510
-31% -$12.6M 4.78% 11
2025
Q3 		$35.5M Buy
292,137
+134,276
+85% +$15.1M 8.16% 4
2025
Q2 		$16.5M Buy
157,861
+56,621
+56% +$6M 5% 10
2025
Q1 		$11.8M Sell
101,240
-148,529
-59% -$16.9M 6.06% 7
2024
Q4 		$21.1M Buy
249,769
+158,048
+172% +$14.5M 4.38% 7
2024
Q3 		$8.24M Sell
91,721
-214,792
-70% -$18.7M 1.97% 17
2024
Q2 		$24.7M Buy
306,513
+203,802
+198% +$15.1M 6.24% 6
2024
Q1 		$8.2M Sell
102,711
-28,027
-21% -$2.35M 2.84% 16
2023
Q4 		$10.4M Sell
130,738
-11,772
-8% -$787K 4.76% 10
2023
Q3 		$9.96M Sell
142,510
-57,570
-29% -$4.3M 3.18% 10
2023
Q2 		$14.4M Buy
200,080
+50,875
+34% +$3.75M 5.34% 6
2023
Q1 		$9.2M Sell
149,205
-50,849
-25% -$3.34M 2.8% 12
2022
Q4 		$15.4M Buy
+200,054
New +$12M 6.24% 4

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tri Locum Partners's AXSM Position: Q2 2026 in Review

Tri Locum Partners increased its Axsome Therapeutics (AXSM) stake by 253% in Q2 2026, buying an estimated $34.1M and bringing the position to 219,308 shares worth $53.7M. The position accounts for 6.6% of the portfolio, ranked #6.

Tri Locum Partners first reported a position in AXSM in Q4 2022 and has held it in 15 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Tri Locum Partners held 219,308 shares of Axsome Therapeutics worth $53.7M as of Q2 2026.
  • Tri Locum Partners bought 157,192 Axsome Therapeutics shares in Q2 2026, an estimated $34.1M.
  • Axsome Therapeutics made up 6.6% of Tri Locum Partners's portfolio in Q2 2026, its #6 holding.
  • Tri Locum Partners first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.